Du, Liying
Lilly (China)
2 papers on CoChat
Most cited papers
- Verified
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 104
- Verified
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo
Ma, J., Liu, M., Wang, R., Du, L., & Ji, L. (2024) · Diabetes Obesity and Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 12
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free